Trends News Trends In Small Cell Lung Cancer Incidence And Survival
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Trends News Trends In Small Cell Lung Cancer Incidence And Survival is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Lung Cancer Survival Has Improved in US, American Lung Association Report Shows
In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ... Read More
A Chicago Grandmother’s Seven-Year Journey with Small-Cell Lung Cancer: A Fight for Time, Hope, and Progress
Maida Mangiameli, 75, has defied the odds by surviving over seven years with small-cell lung cancer—a disease with a five-year survival rate of just 5–10% according to the National Cancer Institute. Read More
Decline in SCLC Incidence Expected to Accelerate Through 2050
SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study used SEER 17 data, showing a steady decline in SCLC cases across ... Read More
SABR Ties SOC Surgery in Non-Small Cell Lung Cancer Survival
Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ... Read More
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ... Read More
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in ... Read More
Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
The HARMONi-A study is the first Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in ... Read More
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus